Background: Maternal obesity is a well established risk factor for gestational diabetes but it is not known if the pattern of maternal fat distribution predicts adverse pregnancy outcomes.
Introduction
There is substantial evidence that obesity in pregnancy contributes to increased complications including mortality for both mother and baby. The Confidential Enquiry into Maternal and Child Health (2007) reported that 35% of women who had died had a recorded body mass index (BMI) of 30 or more and furthermore 30% of the mothers who had experienced a stillbirth or neonatal death were obese. 1 Obese women are also at increased risk of gestational diabetes (GDM). In a prospective study of more than 16,000 patients with BMI 30-40, the odds ratio (OR) for GDM were 2.6 (95% confidence interval (CI) 2.4-6.0) compared with women with BMI 530. 2 More recently, a meta analysis of 70 studies found the OR for GDM was 3.01 (95% CI 2.34-3.87) for moderate obesity and 5.55 (95% CI 4.27-7.21) for women with morbid obesity (BMI 440) compared with normal weight women. 3 Similar results were reported by Chu et al. 4 Despite these consistent results, there is still uncertainty regarding the relative importance of the distribution of the fat and the risk of GDM. While central obesity and by implication, visceral fat mass (VFM), is well established as a risk factor for type 2 diabetes and the metabolic syndrome, there are no published data on the possible association of VFM in pregnancy and risk of GDM. We investigated the relation of fat distribution (total percentage fat, VFM and waist: hip ratio (WHR)) and risk of GDM in a cohort of obese women with no known diabetes attending a weight management clinic.
Methods

Subjects
We enrolled 302 consecutive obese pregnant women with no known diabetes attending the weight management clinic at St Helier Hospital, Carshalton, Surrey, UK. The median age of these women was 31 years (range, 26-34 years) and the median BMI was 38.2 kg/m 2 (range, 36.1-41.4); 74.5% of these women were Caucasians. All women received standardised dietary and exercise advice. Maternal baseline characteristics are shown in Table 1 .
Gestational diabetes
All women underwent a 75 g oral glucose tolerance test at around 28 weeks gestation; GDM was defined by WHO criteria. 5 Seventytwo of the 302 enrolled patients subsequently developed GDM (23.8%) and were medically managed in the joint antenatal obstetric and diabetic clinic by a standard protocol. They performed home glucose monitoring four times daily and if three or more tests were outside target range (55.6 mmol/l (fasting), 58 mmol/l (1 h post-prandial) and 57 mmol/l (2 h post-prandial), they were commenced on metformin. Additional insulin was prescribed if tests remained suboptimal despite maximal metformin.
Fat distribution
All women underwent body composition analysis at booking (median gestation ¼ 15 weeks; range, 14-17 weeks) using Inbody 720 Õ bioimpedence. The instrument performs body composition analysis using Direct Segmental Multi-frequency Bioelectrical Impedence Analysis Method (DSM-BIA Method). It measures weight, BMI, WHR, lean body mass, total percentage body fat (PBF) and VFM. It is a validated tool correlating well with intraabdominal fat area assessed by computed tomography (CT) 6 and dual-energy X-ray absorptiometry (DEXA). 7 It has also been used in patients with obesity. 8, 9 It has been shown to be safe in the second and third trimesters of pregnancy and validated against deuterium and hydrodensitometry techniques for body composition analysis. 10, 11 DSM-BIA is also an accurate technique for assessing body water distribution, which changes during pregnancy. 12 There is no evidence that the physiological alterations in body water are different in pregnancies complicated by GDM. In this study, Inbody R assessment was repeated at 36 weeks gestation in Group 1 patients to assess changes during pregnancy on treatment.
Statistical analysis
The maternal baseline characteristics, pregnancy and neonatal outcome in patients developing GDM (Group 1, n ¼ 72) were compared with those with normal glucose tolerance (Group 2, n ¼ 230). Group data were compared by 2 2 Â 2 contingency tables and by unpaired t-tests; significance was taken as p50.05. Results are expressed as mean (SD) or median (range) if non-parametric distribution. Pearson's correlation coefficient was used to compare continuous variables.
Results
Women developing GDM (Group 1) were significantly older, more likely to have a history of previous GDM, or a family history of diabetes, or a past history of polycystic ovaries when compared with those remaining normoglycaemic (Group 2) (see Table 1 ). Group 1 women had significantly higher mean fasting glucose (5.04 AE 2.01) compared with Group 2 (4.57 AE 0.83) and higher mean 2-h glucose values (6.32 AE 2.91 versus 5.44 AE 1.29); p50.01. Group 1 women also had higher mean BMI, greater WHR and significantly greater VFM compared with those in Group 2 (see Table 2 ). However, total PBF was very similar in both groups.
The maternal and neonatal outcomes were not significantly different in the two groups except for neonatal hypoglycaemia, which was significantly higher in the diabetic group (see Tables 3 and 4 ).
VFM but not total PBF correlated with fasting glucose values in the whole cohort (r ¼ 0.21, p50.001) and particularly in Group 1 (r ¼ 0.35; p50.002). There was no significant correlation between VFM and 2 h glucose values in the whole cohort or in the two groups.
There was a significant correlation between glycaemia (HBA1c) and maternal BMI (r ¼ 0.39, p50.001), and between HbA1c and VFM (r ¼ 0.47, p50.0001) (see Figure 1 ). No significant correlation was found between HbA1c and total PBF (r ¼ 0.16, p ¼ NS).
We also studied possible associations with baby birth weight (BW). Maternal BMI (r ¼ 0.14; p ¼ 0.02), VFM (r ¼ 0.17; p ¼ 0.002) but not PBF for the whole cohort and particularly in Group 2 (r ¼ 0.21; p ¼ 0.001) had weak but significant correlations with baby weight. Although the expected increase in mean VFM at 36 weeks was reduced by metformin compared with those in Group 1 on dietary measures alone, the difference was not statistically significant (3.76 AE 3.1(SEM) versus 8.24 AE 2.6 (SEM); NS).
Discussion
To our knowledge, this is the first article to examine the possible role of directly measured VFM in relation to pregnancy outcomes. The novel finding in our study is that in addition to well-established predictors of GDM (maternal age, BMI, family history of GDM, history of polycystic ovary syndrome), visceral fat (and not total fat) assessed at antenatal booking is another risk factor for GDM. 13 VFM correlated with fasting glucose in all patients, particularly those developing GDM, as well as long-term measures of HbA1c. Proxy measures of visceral fat, such as waist circumference and WHR showed the expected correlation.
Although obese patients will be expected to have higher VFM, we found no correlation between total PBF and indices of HbA1c (fasting or 2 h glucose), suggesting that non-visceral fat (e.g. subcutaneous fat) does not have the same metabolic implications. This is in keeping with concept of the metabolic syndrome and the proposal as long ago as 1997 that GDM should be considered a component of the metabolic syndrome. 14, 15 A strong association between measures of abdominal obesity (waist circumference, WHR and CT-assessed intra-abdominal fat area) and the development of type 2 diabetes is well established: a meta-analysis of 15 cohorts from 10 longitudinal studies gave a pooled OR for the incidence of diabetes of 2.14 (95% CI: 1.70-2.71) 16 compared with controls. Visceral fat assessed by CT remained a significant predictor of incident diabetes even after adjustment for BMI, total body fat and subcutaneous fat. In a large prospective study of obese non-diabetic subjects, baseline VFM measured by DEXA and magnetic resonance imaging but not general adiposity was independently associated with risk of development of prediabetes and diabetes. 17 These studies point to an important role for visceral fat accumulation in the development of glucose intolerance.
In agreement with a recently published study, Asians developing GDM had lower BMI, lower WHR and lower VFM compared with Caucasians. 18 However, among the Asian cohort, those developing GDM had higher VFM and markers of central obesity. Despite only small numbers in this study, these observations are in keeping with the suggestion that Asians are particularly susceptible to diabetes even at lower BMIs.
The pathogenic mechanism linking visceral fat and the onset of diabetes is likely to be through the development of insulin resistance although we cannot completely exclude the possibility of an effect on insulin secretion. In patients with established type 2 diabetes, visceral fat accumulation has a significant negative impact on glycaemic control through decreased insulin sensitivity. 19 Visceral adipocytes release a variety of inflammatory cytokines that are able to induce insulin resistance such as interleukin-1, interleukin-6, tumour necrosis factor and resistin as well as others such as adiponectin, which improves insulin sensitivity. 19, 20 Adiponectin is down-regulated in obesity and plasma levels are lower in obese subjects compared with controls. 21 Future studies need to examine the concentration of these substances in normal pregnancies and those complicated by obesity and GDM.
A major concern in pregnancies complicated by GDM or obesity is the increased risk of fetal macrosomia. The risk associated with obesity is increased two-to three fold and appears to correlate with the degree of obesity. 22 We noted a positive correlation between maternal BMI and baby BW and between VFM (but not PBF) and BW. On further analysis, these correlations were not found in Group 1 women, reflecting the influence of treatment (metformin and insulin) on perinatal outcomes. We have previously shown a favourable effect of metformin on the incidence of macrosomia in GDM women. 23 Furthermore, we found no significant difference between BWs in the two groups in this study, which is likely to reflect the beneficial effect of metformin in GDM babies. In addition, a reduction in the expected increase in VFM was demonstrated in metformin-treated women, although this observation needs confirmation with larger numbers of patients.
Strengths of this study are direct measurement of fat distribution in vivo in early pregnancy in ambulant women attending a single centre with standardised dietary and exercise advice. There was complete data on all 302 women.
Limitations are the lack of a normal weight cohort of women to act as controls to allow calculation of OR for VFM. We were not able to measure cytokines such as adiponectin or inflammatory markers such as C-reactive protein, which might have added useful information regarding the metabolic syndrome. Also insulin sensitivity and secretion were not measured in this study. Future research will address this issue.
Conclusions
The results of this study add to the growing evidence of the importance of central obesity and in particular VFM in the development of GDM. While BMI is a convenient measure of obesity, routine measurement of waist circumference or WHR in early pregnancy ideally complemented by VFM assessments may help identify those patients at increased risk.
